Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2014
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.
СтатьяПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jagasia Madan H, Greinix Hildegard T, Arora Mukta, Williams Kirsten M, Wolff Daniel, Cowen Edward W, Palmer Jeanne, Weisdorf Daniel, Treister Nathaniel S, Cheng Guang-Shing, Kerr Holly, Stratton Pamela, Duarte Rafael F, McDonald George B, Inamoto Yoshihiro, Vigorito Afonso, Arai Sally, Datiles Manuel B, Jacobsohn David, Heller Theo, Kitko Carrie L, Mitchell Sandra A, Martin Paul J, Shulman Howard, Wu Roy S, Cutler Corey S, Vogelsang Georgia B, Lee Stephanie J, Pavletic Steven Z, Flowers Mary E D
Аннотация
The 2005 National Institutes of Health (NIH) Consensus Conference proposed new criteria for diagnosing and scoring the severity of chronic graft-versus-host disease (GVHD). The 2014 NIH consensus maintains the framework of the prior consensus with further refinement based on new evidence. Revisions have been made to address areas of controversy or confusion, such as the overlap chronic GVHD subcategory and the distinction between active disease and past tissue damage. Diagnostic criteria for involvement of mouth, eyes, genitalia, and lungs have been revised. Categories of chronic GVHD should be defined in ways that indicate prognosis, guide treatment, and define eligibility for clinical trials. Revisions have been made to focus attention on the causes of organ-specific abnormalities. Attribution of organ-specific abnormalities to chronic GVHD has been addressed. This paradigm shift provides greater specificity and more accurately measures the global burden of disease attributed to GVHD, and it will facilitate biomarker association studies.